Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age
PBLSL predicted efficacy and prognosis in various patient stratifications, suggesting PBLSL is a reliable predictor for CRT and CRIT in advanced lung cancer. Detecting different cellular subpopulations helps identify patients with significant treatment responses across different stratifications.
Authors
- Yuanji Chen (ORCID: https://orcid.org/0009-0005-4072-2870)
- Cunliang Wang (ORCID: https://orcid.org/0000-0003-4495-7456)
- Xudong Hu (ORCID: https://orcid.org/0000-0002-2141-5657)
- Zeliang Ma (ORCID: https://orcid.org/0000-0001-8250-0540)
- Chuanwang Miao
- Hao Zhang (ORCID: https://orcid.org/0000-0002-4582-2556)
- Shan Zhu (ORCID: https://orcid.org/0000-0003-1531-6174)
- Wei Zhao (ORCID: https://orcid.org/0000-0002-5811-1710)
Institutions
- Shandong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Linyi People's Hospital (CN)
- Shandong Tumor Hospital (CN)
- Shandong Provincial Hospital (CN)
- Mayo Clinic in Arizona (US)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3389/fimmu.2024.1464728
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Natural Science Foundation of Shandong Province